Intra-Cellular Therapies Files Supplemental NDA for Caplyta as Adjunctive Treatment for Major Depressive Disorder
Express News | Intra-Cellular Therapies Submits Supplemental New Drug Application (Snda) to FDA for Caplyta® (Lumateperone) for the Treatment of Major Depressive Disorder as Adjunctive Therapy
Jefferies Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Maintains Target Price $105
Mizuho Securities Maintains Intra-Cellular Therapies(ITCI.US) With Buy Rating, Announces Target Price $100
RBC Capital Sticks to Their Buy Rating for Intra-Cellular Therapies (ITCI)
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
